A new way of taking Tysabri (natalizumab) has been approved for the UK and Ireland.
The MHRA (Medicines and Healthcare products Regulatory Agency) and European Commission have granted marketing authorisation for an under-the-skin (subcutaneous) injection of Tysabri.
At the moment, it takes several hours to have a Tysabri infusion in a hospital clinic and some people have to travel a long distance to get to their infusion clinic.
Subcutaneous injections will take less time than the infusion and could be given in a clinic closer to home, such as at a local hospital or health centre. Monthly subcutaneous Tysabri will be given by a health professional.
Clinical trials have shown that monthly subcutaneous injections of Tysabri are as effective as monthly infusions at reducing relapses and lesions seen on MRI scans. About 7% of people (less than 1 in 10) experienced mild or moderate injection site reactions when having a subcutaneous injection of Tysabri.
More about Tysabri
Tysabri is a disease modifying drug for very active relapsing remitting MS (two or more relapses in one year, with signs of increasing or new lesions between two consecutive MRI scans). It reduces the number of relapses by about two thirds (70%), compared to taking placebo.
Common side effects include dizziness, nausea, urticaria (a skin rash) and shivering. Treatment with Tysabri may increase the risk of progressive multifocal leukoencephalopathy (PML), an uncommon brain infection.
Ponesimod (Ponvory) for relapsing remitting multiple sclerosis rejected by NICE
13 Oct 2021 - 00:00
The MS Trust is very disappointed that NICE does not recommend ponesimod (Ponvory) as an NHS treatment in England and Wales.
Multiple sclerosis and disease modifying drugs, what are my options?
28 Sep 2021 - 00:00
We interview Dr Sharmilee Gnanapavan, a Consultant Neurologist at Bart's Health to get some answers on what's new in the world of disease modifying drugs and multiple sclerosis.
New report highlights barriers to accessing Sativex across the UK
18 Aug 2021 - 00:00
Fewer than 13% of people in England eligible for Sativex can access it, according to a new report published today. People living in Wales, Scotland and Northern Ireland also face difficulties.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.